The mechanism we're betting on.
Mixed-aetiology cognitive decline targeting vascular, metabolic, and inflammatory contributors. Cognitive-battery primary, MRI volumetric secondary, plasma p-tau and Aβ42/40 ratio as molecular gates. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated
What the rest of the world is doing.
Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Dementia / Cognitive Health indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →
- No PubMed papers surfaced for this indication in the current refresh.
Locked before readout.
Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated
Same stack, every indication.
- M2 · Pre-Registration — SHA-256 locking before readout.
- M1 · IBC Reasoning — 19-agent audit (11 core + 8 reasoning nodes).
- M3 · Cross-Trial Validation — mechanism-anchored bridging across indications.
- M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR feeds (the source of the numbers above).
Want the full Dementia / Cognitive Health protocol?
The abstract above is open. Compound lists, dose escalations, SHA-256-locked prediction documents, agent-network reasoning chains, and trial design specifics are available to verified clinicians, indication researchers, and sponsors under MNDA. Contact management to begin the access request.
Contact management →